Bionano Genomics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-26.4M | $-112.0M | $-232.5M | $-132.6M | $-72.4M | $-41.1M | $-29.8M | $-18.5M |
| Depreciation & Amortization | $9.5M | $14.0M | $13.7M | $9.6M | $3.4M | $1.5M | $1.1M | $1.3M |
| Depreciation | $4.2M | $4.9M | $6.5M | $3.8M | $1.9M | $1.4M | $1.1M | — |
| Amortization | $5.4M | $6.6M | $7.2M | $5.8M | $1.4M | $100.0K | — | — |
| Stock-Based Compensation | $4.5M | $9.7M | $15.2M | $22.4M | $9.7M | $1.6M | $1.3M | $1.2M |
| Net Cash from Operating Activities | $-16.3M | $-68.9M | $-125.2M | $-124.8M | $-71.9M | $-38.3M | $-29.5M | $-19.9M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | $0 | $61.1K | $331.7K |
| Business Acquisitions | — | — | $0 | $31.3M | — | $2.4M | $0 | — |
| Net Cash from Investing Activities | $-12.7M | $73.8M | $24.2M | $82.8M | $-278.1M | $-2.5M | $-61.1K | $-331.7K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $24.0M | $-13.7M | $113.8M | $23.0M | $336.1M | $61.9M | $30.4M | $35.8M |
| Net Change in Cash | $-5.1M | $-8.8M | $12.9M | $-19.1M | $-13.9M | $21.1M | $788.6K | $15.5M |
| Free Cash Flow | — | — | — | — | — | $-38.3M | $-29.6M | $-20.3M |